Please enable JS

DISCOVER

OFFICE & SUBSIDIARY

Offices
& Subsidiary

HEADQUARTERS
TELEMEDICINE TECHNOLOGIES S.A.S.

121 rue d’Aguesseau
92100, Boulogne-Billancourt,
France
To join us : Telemedicine Technologies Headquarters

SUBSIDIARY
Belgium – Liège
TELEMEDICINE TECHNOLOGIES Belgium SA

Rue des Guillemins, 139
B-4000 Liège
Belgium

OFFICES
R&D office

Laval
France

A LEADING POSITION AND
AN INTERNATIONAL DEPLOYMENT

64 +

countries
involved

20 000 +

investigational
Centres

2 million +

patients
in database

50 000 +

users
worlwide

telemedicine technologies earth

LATEST NEWSOUR NEWS >

telemedecine technologies news

TELEMEDICINE TECHNOLOGIES acquires the start-up CTMA and its software suite CT-SCOUT and ToTem4me, to strengthen and accelerate patient recruitment in clinical trials

January 19, 2023

Telemedicine Technologies continues to acquire companies that provide innovative solutions and services to its customers. The acquisition of the CTMA (Clinical Trials Mobile Application) software suite enables Telemedicine Technologies to offer investigating centres assistance to accelerate patient recruitment in clinical trials, and to ensure their commitments to sponsors. The digital transformation of healthcare institutions is […]

READ MORE
telemedecine technologies news

Trialbee inks deal with Acclinate in push for trial diversity 

December 19, 2022

Fierce Biotech Trialbee, a patient enrollment company, inked a partnership deal with Acclinate in a push to accelerate wider patient diversity in clinical trials. Under the partnership, Sweden-based Trialbee will get access to Acclinate’s NOWINCLUDED offering that engages diverse populations on health-related issues, the company said in a Dec. 13 press release. Founded in 2020, Birmingham, Alabama-based […]

READ MORE
telemedecine technologies news

Regulators Speak About Decentralized Clinical Trials

December 19, 2022

Applied Clinical Trials The concept of decentralized clinical trials (DCT) is still in its infancy in the industry, although the pandemic has facilitated its adoption. FDA has issued a guidance document for operating under the pandemic, as did EMA which outline several characteristics of DCTs, including remote study visits, clinical outcomes assessments (COAs), monitoring and inspections, to name […]

READ MORE